Home/Healthcare/Clinical Trials/Contract Research Organizations (CRO) Services Market

Contract Research Organizations (CRO) Services Market - Strategic Insights and Forecasts (2026-2031)

Market Size, Share, Forecasts and Trends Analysis By Molecule Type (Vaccines, Cell Gene Therapy, Others), Type (Early Phase Development Services, Clinical Research Services, Laboratory Services, Consulting Services), Therapeutic Area (Oncology, CNS Disorders, Other Therapeutic Areas), By End User (Pharmaceuticals and Biopharmaceuticals Companies, Medical Devices Companies, Academic Institutes), and Region

$3,950
Single User License
Report OverviewSegmentationTable of ContentsCustomize Report

Report Overview

The global contract research organization (CRO) service market is set to reach USD 186.317 billion in 2031, growing at a CAGR of 7.22% from a valuation of USD 131.459 billion in 2026.

Contract Research Organizations (CRO) Services Market - Strategic Insights and Forecasts (2026-2031) market growth projection from $131.46B in 2026 to $186.32B by 2031 at a CAGR of 7.22%.
Contract Research Organizations (CRO) Services Market - Strategic Insights and Forecasts (2026-2031) market growth projection from $131.46B in 2026 to $186.32B by 2031 at a CAGR of 7.22%.
Contract Research Organizations (CRO) Highlights
Increasing outsourcing of R&D activities by pharmaceutical and biotechnology companies to leverage specialized expertise and accelerate drug development timelines.
Growing demand for CROs with deep capabilities in specialized therapeutic areas, including oncology, rare diseases, cell and gene therapies, and precision medicine.
Widespread adoption of advanced technologies such as AI, machine learning, and data analytics to enhance trial efficiency, data quality, and decision-making processes.
Shift toward decentralized and hybrid clinical trial models to improve patient engagement, accessibility, and overall trial performance.

The market for global contract research organisation (CRO) services is critical to providing outsourced research and development (R&D) solutions for the pharmaceutical, biopharmaceutical, and medical device industries. CRO's specialised service offerings, such as preclinical studies, clinical trial activities, laboratory testing, and regulatory consulting, allow the Pharmaceutical, Biopharmaceutical, and Medical Device industries to develop new therapies faster and at a lower cost.

The main drivers of growth in the CRO services market are the increasing demand for new and innovative therapies, the biopharmaceutical industry's ongoing trend of outsourcing, and the need to create efficiencies in clinical development. By developing products to meet the diverse needs and capabilities of successful healthcare companies worldwide, CROs have continued to foster and drive innovation while reducing operational burdens on these companies.

Contract Research Organizations (CRO) Services Market Trends:

The Contract Research Organisation (CRO) Services market includes professional services provided by research organisations that focus on contract clinical trials and bioavailability and/or bioequivalence studies on behalf of sponsors involved in developing new drugs. In India, the Government of India’s Ministry of Health & Family Welfare amended the New Drugs & Clinical Trial Regulations via G.S.R. 581 (E) dated 19 September 2024, with an effective date of 1 April 2025.

It defined CROs and began a regulatory system for dictating how CROs will be registered and operated. Specifically, as per these amended regulations, only CROs that have received registration from the Central Licensing Authority (CLA) are permitted to conduct clinical trials or other studies involving human subjects.

To help CROs comply with this new rule, the Central Drugs Standard Control Organisation, a part of the Government of India, has employed an online registry through the SUGAM portal. Effective 1 April 2025, it will be required that all CROs process their applications for CRO Registration on the SUGAM portal and submit the required documentation, as well as the appropriate fee, before beginning regulated research activities.

These regulatory changes create a consistent baseline for CRO Services in India. This will allow CROs nationwide to maintain consistency in meeting standardised compliance, oversight, and ethical best practices in their role as part of the National Clinical Research Framework.

Growth of the global drug discovery outsourcing market from USD 3.8 billion in 2022 to an expected USD 6.2 billion by 2031 reflects rising demand for discovery chemical services in pharmaceutical R&D. Surging demand for discovery chemical services feeds directly into the Contract Research Organisation Services market because drug developers are increasingly outsourcing early-stage research work to specialised providers.

As pharmaceutical companies focus internal resources on later-stage development, they rely on CROs for chemistry, biological screening, and lead optimisation expertise, expanding service volumes and revenues across the CRO ecosystem.

Contract Research Organizations (CRO) Services Market Drivers:

  • Rise in the global cases of chronic diseases and demand for new therapies: A global increase in chronic and non-communicable diseases such as cardiovascular disease, cancer, diabetes, and chronic respiratory disorders poses long-term healthcare challenges. Pharmaceutical and biopharmaceutical companies are expanding pipelines to include new therapeutic classes, personalised medicine, and combination therapies, increasing the demand for clinical trials and specialised testing supported by CROs.

  • Growing Investment in Research and Development: Increased investment in research and advanced technologies such as artificial intelligence and data analytics is driving CRO market growth. For instance, in November 2024, AstraZeneca announced an investment of approximately USD 3.5 billion for research and development and manufacturing of new drugs in the United States.

Contract Research Organizations (CRO) Services Market Segment Analysis:

By Molecule Type: Cell Gene Therapy

By molecule type, the Contract Research Organizations (CRO) Services Market is segmented into vaccines, cell gene therapy, and others. The cell gene therapy segment is expected to witness strong demand driven by the rise in chronic and rare genetic diseases, including cancer, cardiovascular disease, genetic disorders, and autoimmune diseases.

Cell and gene therapies involve modification of patient cells and require extensive clinical trial support, regulatory compliance, data management, and patient recruitment. As a result, biopharmaceutical companies increasingly partner with CROs to support these complex development programs.

By End-User: Pharmaceutical and Biopharmaceutical Companies

Pharmaceutical and biopharmaceutical companies represent a dominant end-user segment, driven by significant investment in biologics and therapies targeting life-threatening and rare diseases. Growth in the global clinical trial pipeline and increasing regulatory complexity continue to reinforce reliance on CRO services.

Contract Research Organizations (CRO) Services Market Geographical Outlook:

North America: United States

The pharmaceutical sector in the United States is experiencing a shift toward patient-centric drug development, supported by evolving regulatory guidance from the Food and Drug Administration (FDA). Continued approvals of novel drugs and increased R&D investment are driving demand for specialized CRO expertise.

Strategic collaborations, acquisitions, and government funding through agencies such as the National Institutes of Health further shape the CRO market landscape. However, ongoing tariff pressures and regulatory complexity may introduce operational challenges for CRO service providers.

Contract Research Organizations (CRO) Services Market Developments:

  • April 2026: Parexel acquired Vitrana to enhance AI-driven patient safety and pharmacovigilance solutions, improving automation, compliance, and operational efficiency in clinical development services.

  • February 2026: Worldwide Clinical Trials completed the acquisition of Catalyst Clinical Research, expanding oncology, biometrics, and functional service provider capabilities while strengthening global clinical trial technology and operational reach.

  • January 2026: WEP Clinical acquired Siron Clinical to expand Phase I–IV clinical trial delivery capabilities and strengthen European operations across rare disease and specialized therapeutic research services.

  • July 2025: Medpace raised its full-year revenue guidance following stronger clinical trial demand, reduced cancellations, and improved biotech funding conditions supporting CRO service market recovery.

  • August 2025: IQVIA and Veeva Systems announced long-term global clinical and commercial partnerships integrating software, data, and CRO service platforms for streamlined clinical development operations.

Contract Research Organizations (CRO) Services Market Scope:

Report Metric Details
Total Market Size in 2026 USD 131.459 billion
Total Market Size in 2031 USD 186.317 billion
Forecast Unit Billion
Growth Rate 7.22%
Study Period 2021 to 2031
Historical Data 2021 to 2024
Base Year 2025
Forecast Period 2026 – 2031
Segmentation Molecule Type, Type, Therapeutic Area, End-User
Geographical Segmentation North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies
  • PPD Inc. (Thermo Fisher Scientific Inc)
  • IQVIA Inc
  • ICON Plc
  • Parexel International Corporation
  • NAMSA
  • Labcorp Drug Development
  • WuXi AppTec
  • Syneos Health
  • Evotec SE 
  • Novotech

Contract Research Organizations (CRO) Services Market Segmentation

  • By Molecule Type

    • Vaccines

    • Cell Gene Therapy

    • Others

  • By Type

    • Early Phase Development Services

    • Clinical Research Services

    • Laboratory Services

    • Consulting Services

  • By Therapeutic Area

    • Oncology

    • CNS Disorders

    • Other Therapeutic Areas

  • By End-User

    • Pharmaceuticals and Biopharmaceuticals Companies

    • Medical Devices Companies

    • Academic Institutes

  • By Geography

    • North America

      • United States

      • Canada

      • Mexico

    • South America

      • Brazil

      • Argentina

      • Others

    • Europe

      • United Kingdom

      • Germany

      • France

      • Spain

      • Others

    • Middle East and Africa

      • Saudi Arabia

      • UAE

      • Others

    • Asia Pacific

      • China

      • Japan

      • India

      • South Korea

      • Taiwan

      • Others

Market Segmentation

By Molecule Type (2021-2031)

Vaccines
Cell Gene Therapy
Others

By Type (2021-2031)

Early Phase Development Services
Preclinical
Toxicology Testing
Discovery Studies
Chemistry, Manufacturing, and Controls
Pharmacokinetics /Pharmacodynamics
Clinical Research Services
Phase I
Phase II
Phase III
Phase IV
Phase V
Laboratory Services
Analytical Testing
Bioanalytical Testing
Physical Characterization
Stability Testing, Batch Release Testing
Raw Material Testing
Other Analytical Testing
Consulting Services

By Therapeutic Area (2021-2031)

Oncology
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Others
CNS Disorders
Infectious Diseases
Cardiovascular Diseases
Respiratory Disorders
Diabetes
Other Therapeutic Areas

By End User (2021-2031)

Pharmaceuticals and Biopharmaceuticals Companies
Medical Devices Companies
Academic Institutes

By Geography (2021-2031)

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Taiwan
Others

Table of Contents

1. Executive Summary

2. Market Snapshot

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. Business Landscape

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations

3.7. Strategic Recommendations

4. Technological Outlook

5. Contract Research Organizations (CRO) Services Market By Molecule Type (2021-2031)

5.1. Introduction

5.2. Vaccines

5.3. Cell Gene Therapy

5.4. Others

6. Contract Research Organizations (CRO) Services Market By Type (2021-2031)

6.1. Introduction

6.2. Early Phase Development Services

6.2.1. Preclinical

6.2.2. Toxicology Testing

6.2.3. Discovery Studies

6.2.4. Chemistry, Manufacturing, and Controls

6.2.5. Pharmacokinetics /Pharmacodynamics

6.3. Clinical Research Services

6.3.1. Phase I

6.3.2. Phase II

6.3.3. Phase III

6.3.4. Phase IV

6.3.5. Phase V

6.4. Laboratory Services

6.4.1. Analytical Testing

6.4.2. Bioanalytical Testing

6.4.3. Physical Characterization

6.4.4. Stability Testing, Batch Release Testing

6.4.5. Raw Material Testing

6.4.6. Other Analytical Testing

6.5. Consulting Services

7. Contract Research Organizations (CRO) Services Market By Therapeutic Area (2021-2031)

7.1. Introduction

7.2. Oncology

7.2.1. Breast Cancer

7.2.2. Lung Cancer

7.2.3. Colorectal Cancer

7.2.4. Prostate Cancer

7.2.5. Others

7.3. CNS Disorders

7.3.1. Infectious Diseases

7.3.2. Cardiovascular Diseases

7.3.3. Respiratory Disorders

7.3.4. Diabetes

7.4. Other Therapeutic Areas

8. Contract Research Organizations (CRO) Services Market By End User (2021-2031)

8.1. Introduction

8.2. Pharmaceuticals and Biopharmaceuticals Companies

8.3. Medical Devices Companies

8.4. Academic Institutes

9. Contract Research Organizations (CRO) Services Market By Geography (2021-2031)

9.1. Introduction

9.2. North America

9.2.1. By Molecule Type

9.2.2. By Type

9.2.3. By Therapeutic Area

9.2.4. By End-User

9.2.5. By Country

9.2.5.1. United States

9.2.5.2. Canada

9.2.5.3. Mexico

9.3. South America

9.3.1. By Molecule Type

9.3.2. By Type

9.3.3. By Therapeutic Area

9.3.4. By End-User

9.3.5. By Country

9.3.5.1. Brazil

9.3.5.2. Argentina

9.3.5.3. Others

9.4. Europe

9.4.1. By Molecule Type

9.4.2. By Type

9.4.3. By Therapeutic Area

9.4.4. By End-User

9.4.5. By Country

9.4.5.1. United Kingdom

9.4.5.2. Germany

9.4.5.3. France

9.4.5.4. Spain

9.4.5.5. Others

9.5. Middle East and Africa

9.5.1. By Molecule Type

9.5.2. By Type

9.5.3. By Therapeutic Area

9.5.4. By End-User

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.2. UAE

9.5.5.3. Israel

9.5.5.4. Others

9.6. Asia Pacific

9.6.1. By Molecule Type

9.6.2. By Type

9.6.3. By Therapeutic Area

9.6.4. By End-User

9.6.5. By Country

9.6.5.1. Japan

9.6.5.2. China

9.6.5.3. India

9.6.5.4. South Korea

9.6.5.5. Indonesia

9.6.5.6. Thailand

9.6.5.7. Taiwan

9.6.5.8. Others

10. Competitive Environment and Analysis

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. Company Profiles

11.1. Thermo Fisher Scientific Inc.

11.2. IQVIA Holdings Inc.

11.3. ICON plc

11.4. Parexel International Corporation

11.5. NAMSA

11.6. Labcorp Holdings Inc.

11.7. WuXi AppTec Co., Ltd.

11.8. Syneos Health, Inc.

11.9. Evotec SE

11.10. Novotech Health Holdings Pte. Ltd.

11.11. CliniExperts Inc.

11.12. PharPoint Research, Inc.

11.13. Veranex

12. Research Methodology

List of Figures

List of Tables

Contract Research Organizations (CRO) Services Market Report

Report IDKSI061615663
PublishedFeb 2026
Pages148
FormatPDF, Excel, PPT, Dashboard

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Frequently Asked Questions

The global Contract Research Organizations (CRO) services market is set to reach USD 186.317 billion in 2031, growing at a Compound Annual Growth Rate (CAGR) of 7.22% from a valuation of USD 131.459 billion in 2026. This significant growth underscores the increasing reliance on outsourced R&D solutions across the healthcare sector.

The report indicates a growing demand for CROs possessing deep capabilities in highly specialized therapeutic areas. These include oncology, rare diseases, advanced cell and gene therapies, and precision medicine, reflecting the industry's focus on complex and targeted treatment development.

Key drivers include the increasing outsourcing of R&D by pharmaceutical and biotechnology companies to leverage specialized expertise and accelerate drug development timelines, coupled with the rising demand for new innovative therapies. Technologically, the market is being shaped by the widespread adoption of AI, machine learning, and data analytics to enhance trial efficiency, alongside a significant shift towards decentralized and hybrid clinical trial models.

The report details a significant regulatory development in India, where the Government’s Ministry of Health & Family Welfare amended the New Drugs & Clinical Trial Regulations via G.S.R. 581 (E) dated 19 September 2024, effective 1 April 2025. This amendment mandates that only CROs registered with the Central Licensing Authority (CLA) via the SUGAM portal are permitted to conduct clinical trials or studies involving human subjects, establishing a new framework for their operation.

CROs offer a critical suite of specialized service offerings vital for accelerating new therapy development and reducing associated costs. These services encompass preclinical studies, comprehensive clinical trial activities, advanced laboratory testing, and essential regulatory consulting for the pharmaceutical, biopharmaceutical, and medical device industries.

CROs contribute by developing products and services that meet the diverse needs and capabilities of healthcare companies worldwide, thereby fostering and driving innovation. Their outsourced R&D solutions help pharmaceutical, biopharmaceutical, and medical device industries develop new therapies faster, achieve greater efficiencies in clinical development, and significantly reduce their operational burdens.

Need data specifically for your business?Request Custom Research →

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon